Engineering aggregation-resistant antibodies
JM Perchiacca, PM Tessier - Annual review of chemical and …, 2012 - annualreviews.org
The ability of antibodies to bind to target molecules with high affinity and specificity has led
to their widespread use in diagnostic and therapeutic applications. Nevertheless, a limitation …
to their widespread use in diagnostic and therapeutic applications. Nevertheless, a limitation …
Toward aggregation-resistant antibodies by design
CC Lee, JM Perchiacca, PM Tessier - Trends in biotechnology, 2013 - cell.com
Monoclonal antibodies are attractive therapeutics for treating a wide range of human
disorders due to their exquisite binding specificity and high binding affinity. However, a …
disorders due to their exquisite binding specificity and high binding affinity. However, a …
Principles and engineering of antibody folding and assembly
Antibodies are uniquely suited to serve essential roles in the human immune defense as
they combine several specific functions in one hetero-oligomeric protein. Their constant …
they combine several specific functions in one hetero-oligomeric protein. Their constant …
[HTML][HTML] Prediction and reduction of the aggregation of monoclonal antibodies
R van der Kant, AR Karow-Zwick, J Van Durme… - Journal of molecular …, 2017 - Elsevier
Protein aggregation remains a major area of focus in the production of monoclonal
antibodies. Improving the intrinsic properties of antibodies can improve manufacturability …
antibodies. Improving the intrinsic properties of antibodies can improve manufacturability …
Advances in antibody design
KE Tiller, PM Tessier - Annual review of biomedical engineering, 2015 - annualreviews.org
The use of monoclonal antibodies as therapeutics requires optimizing several of their key
attributes. These include binding affinity and specificity, folding stability, solubility …
attributes. These include binding affinity and specificity, folding stability, solubility …
Antibody structure and function: the basis for engineering therapeutics
ML Chiu, DR Goulet, A Teplyakov, GL Gilliland - Antibodies, 2019 - mdpi.com
Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …
Aggregation, stability, and formulation of human antibody therapeutics
D Lowe, K Dudgeon, R Rouet, P Schofield… - Advances in protein …, 2011 - Elsevier
Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …
stability and a propensity to aggregate. These unfavorable tendencies can be even more …
Antibody therapeutics, antibody engineering, and the merits of protein stability.
SJ Demarest, SM Glaser - Current opinion in drug discovery & …, 2008 - europepmc.org
Antibodies are highly soluble, multidomain proteins that are well suited for
biopharmaceutical development; however, engineering antibodies to perform novel …
biopharmaceutical development; however, engineering antibodies to perform novel …
Engineered autonomous human variable domains
J Nilvebrant, PM Tessier… - Current pharmaceutical …, 2016 - ingentaconnect.com
Background: The complex multi-chain architecture of antibodies has spurred interest in
smaller derivatives that retain specificity but can be more easily produced in bacteria …
smaller derivatives that retain specificity but can be more easily produced in bacteria …
Antibody aggregation: insights from sequence and structure
Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …